On 31 March, 2025, Kazia Therapeutics (Australia) Announced sale of intellectual property and trademarks rights for Cantrixil, a product that has been discussed earlier on Cyclodextrin News Blog [1]. Kazia will receive USD $1 million from Vivesto AB (Sweden) for the intellectual property and trademark assets rights to the oncology drug candidate, Cantrixil that has received orphan drug designation from FDA [2,3].
In March 2021, Vivesto licensed the exclusive global development and commercialization rights for Cantrixil from Kazia Therapeutics. Having decided not to pursue development of Cantrixil in ovarian cancer, which was the original focus of the license agreement, Vivesto is currently exploring Cantrixil preclinically for the treatment of hematological cancers. Cantrixil, a legacy molecule in the Kazia pipeline, is a product candidate consisting of the active molecule, a potent and selective third generation benzopyran SMETI inhibitor named TRXE-002-01, encapsulated in α-cyclodextrin, according to the corresponding Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 [4].
Interestingly the highest development stage of the molecule was Phase I, wherein the product indication was ovarian, fallopian tube, or peritoneal cancer, the application route was a rare procedure: intra-peritoneal and the vehicle was 20% betadex sulfobutylether sodium (namely Dexolve-7, which is the product of Cyclolab) back in 2018 [5]. The application route of the new, α-cyclodextrin aided formulation is not yet disclosed.
[3] https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=474815
[4] https://www.sec.gov/Archives/edgar/data/1075880/000119312525067910/d939124d424b3.htm
[5] https://cdn.clinicaltrials.gov/large-docs/71/NCT02903771/Prot_000.pdf